- Supply chain solutions company, Celestica (TSX:CLS) has won a contract to manufacture ventilators for Canadian COVID-19 patients
- The company will build 7,500 ventilators for Canadian medical device company, StarFish Medical
- The contract forms part of StarFish’s efforts towards the Canadian Emergency Ventilators project
- Celestica plans to deliver the products to Health Canada for distribution early in 2020’s fourth quarter
- Celestica (CLS) is up 3.42 per cent and is currently trading at C$6.20 per share
Supply chain solutions company, Celestica (TSX:CLS) has won a contract to manufacture ventilators for Canadian COVID-19 patients.
Canadian medical device company, StarFish Medical, has contracted Celestica to build 7,500 ventilators. The company will do so at its operations in Newmarket, Ontario.
StarFish chose Celestica as the manufacturer because of its extensive experience in design, supply chains, and ISO 13485-certified manufacturing. Celestica’s adherence to regulatory requirements also played a part in the decision.
Celestica’s Vice President of HealthTech, Kevin Walsh, welcomed the contract.
“We are proud to partner with StarFish Medical in supplying the ventilators that healthcare professionals must have to treat COVID-19 patients who are in critical condition.
“It’s a Canada-for-Canada alliance that will help to ensure our hospitals and healthcare workers have the equipment they need to save lives,” he said.
StarFish Medical leads the Canadian Emergency Ventilators project. The project forms part of the Canadian Government’s response to the ongoing COVID-19 pandemic.
The initiative aims to bring over 30,000 ventilators to market, in order to meet the demand for such life-saving equipment.
StarFish Medical’s Executive Vice President of Strategic Relationships, John Walmsley, commented on the collaboration with Celestica.
“We’re working on a very short timetable. Celestica’s expertise and capabilities across the entire product development cycle will ensure we can meet the deadline and deliver products of the highest quality,” he said.
With no time to spare, Celestica will begin manufacturing the ventilators this month. The company plans to deliver the finished products for distribution, early in 2020’s fourth quarter.
Celestica (CLS) is up 3.42 per cent and is trading at $6.20 per share at 2:26pm EDT.